LLY - Lexicon Buoyed By Renewed Enthusiasm For The Pipeline
- Lexicon shares have shot higher in just a month, buoyed by an FDA Fast Track designation for LX9211 and positive clinical data from sotagliflozin.
- Multiple SGLT-2 inhibitors have shown cardiac outcome benefits, and I remain unconvinced that sotagliflozin can separate itself from the pack of established, commercialized SGLT-2's.
- Getting the Fast Track nod should shave a year or so off of LX9211's development timeline, but investors are still awaiting proof of efficacy.
- Lexicon shares now trade a little above my estimate of LX9211's value, bringing the future/commercial viability of sotagliflozin back into the investment debate.
For further details see:
Lexicon Buoyed By Renewed Enthusiasm For The Pipeline